$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 21 Dec 2016 | 34739 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Lassa Fever (Lassa Hemorrhagic Fever) Overview 7

    Therapeutics Development 8

    Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Overview 8

    Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis 9

    Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Development by Companies 10

    Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 11

    Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Products Glance 12

    Early Stage Products 12

    Lassa Fever (Lassa Hemorrhagic Fever) - Products under Development by Companies 13

    Lassa Fever (Lassa Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 14

    Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development 15

    Arno Therapeutics Inc 15

    Celgene Corp 16

    Etubics Corp 17

    Kineta Inc 18

    Profectus BioSciences Inc 19

    SIGA Technologies Inc 20

    Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment 21

    Assessment by Monotherapy Products 21

    Assessment by Target 22

    Assessment by Mechanism of Action 24

    Assessment by Route of Administration 26

    Assessment by Molecule Type 28

    Drug Profiles 30

    AR-12 - Drug Profile 30

    Product Description 30

    Mechanism Of Action 30

    R&D Progress 30

    CC-11050 - Drug Profile 33

    Product Description 33

    Mechanism Of Action 33

    R&D Progress 33

    DEF-201 - Drug Profile 34

    Product Description 34

    Mechanism Of Action 34

    R&D Progress 34

    FBH-003 - Drug Profile 36

    Product Description 36

    Mechanism Of Action 36

    R&D Progress 36

    KIN-1400 - Drug Profile 37

    Product Description 37

    Mechanism Of Action 37

    R&D Progress 37

    lassa fever vaccine - Drug Profile 39

    Product Description 39

    Mechanism Of Action 39

    R&D Progress 39

    lassa fever vaccine - Drug Profile 40

    Product Description 40

    Mechanism Of Action 40

    R&D Progress 40

    lassa fever vaccine - Drug Profile 41

    Product Description 41

    Mechanism Of Action 41

    R&D Progress 41

    LHF-535 - Drug Profile 42

    Product Description 42

    Mechanism Of Action 42

    R&D Progress 42

    ML-29 - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    Monoclonal Antibodies for Lassa Fever - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    Monoclonal Antibodies for Viral Infections - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    Small Molecules for Lassa Fever - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    ST-193 - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects 50

    Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones 51

    Featured News & Press Releases 51

    May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials 51

    Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals 51

    May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 52

    Appendix 53

    Methodology 53

    Coverage 53

    Secondary Research 53

    Primary Research 53

    Expert Panel Validation 53

    Contact Us 53

    Disclaimer 54

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

34739 | GMDHC8837IDB

Number of Pages

54

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018SummaryGlobal Markets Direct's lates...
26 Sep 2018 by Global Markets Direct USD $2,000 More Info
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018SummaryGlobal Markets Direct's lates...
13 Mar 2018 by Global Markets Direct USD $2,000 More Info
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017SummaryGlobal Markets Direct's lates...
31 Mar 2017 by Global Markets Direct USD $2,000 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...